Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 270 Longwood Rd. S HAMILTON ON L8P 0A6 |
Tel: | N/A |
Website: | https://fusionpharma.com |
IR: | See website |
Key People | ||
Mohit Rawat President, Chief Business Officer | John Valliant Chief Executive Officer, Founder, Director | John Crowley Chief Financial Officer |
Eric Burak Chief Technology Officer | Christopher P. Leamon Chief Scientific Officer | Dmitri Bobilev Chief Medical Officer |
Business Overview |
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial. |
Financial Overview |
For the fiscal year ended 31 December 2023, Fusion Pharmaceuticals Inc revenues increased 42% to $2.1M. Net loss increased 8% to $94.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 19% to $65.3M (expense), Interest expense increase from $1.8M to $5.2M (expense). |
Employees: | 113 as of Mar 11, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,619M as of Dec 31, 2023 |
Annual revenue (TTM): | $2.07M as of Dec 31, 2023 |
EBITDA (TTM): | -$97.89M as of Dec 31, 2023 |
Net annual income (TTM): | -$94.90M as of Dec 31, 2023 |
Free cash flow (TTM): | -$85.69M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 84,865,021 as of Apr 3, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |